Vera Therapeutics (VERA) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Vera Therapeutics is set to release its Q2 2025 earnings before the market opens on August 14th, with analysts estimating a loss of ($0.82) per share.
• In the last earnings report on August 5th, Vera missed expectations, reporting a loss of ($1.20) EPS, compared to the previous year's loss of ($0.62) EPS.
• The company's stock has a market cap of $1.23 billion and has seen significant institutional interest, with 99.21% of the stock owned by institutional investors and hedge funds.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.82) per share for the quarter.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same period last year, the business posted ($0.62) earnings per share. On average, analysts expect Vera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Vera Therapeutics Price Performance

Shares of NASDAQ:VERA traded up $0.07 during midday trading on Friday, hitting $19.79. The company had a trading volume of 1,047,828 shares, compared to its average volume of 1,289,860. The business's 50-day simple moving average is $22.95 and its 200-day simple moving average is $25.24. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -5.53 and a beta of 1.17. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 27.68. Vera Therapeutics has a twelve month low of $18.53 and a twelve month high of $51.61.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, Director Patrick G. Enright bought 40,607 shares of the business's stock in a transaction dated Tuesday, June 24th. The shares were acquired at an average price of $22.35 per share, with a total value of $907,566.45. Following the transaction, the director owned 3,596,593 shares of the company's stock, valued at approximately $80,383,853.55. The trade was a 1.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 16.30% of the company's stock.

Hedge Funds Weigh In On Vera Therapeutics

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC raised its stake in Vera Therapeutics by 297.1% during the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company's stock valued at $999,000 after acquiring an additional 62,678 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Vera Therapeutics by 22.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company's stock valued at $2,354,000 after buying an additional 17,907 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Vera Therapeutics by 7.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company's stock worth $753,000 after buying an additional 2,210 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on VERA. Guggenheim reiterated a "buy" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Cantor Fitzgerald decreased their target price on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $85.00 price target (up previously from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. Wolfe Research reaffirmed a "peer perform" rating on shares of Vera Therapeutics in a research report on Monday. Finally, JPMorgan Chase & Co. lowered their price target on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating for the company in a research report on Thursday. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Vera Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $63.00.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.